Nemaura Medical to Present at the Benzinga Global Small Cap Conference
Nemaura Medical, a medical technology firm focused on non-invasive diagnostic devices, will have CEO Faz Chowdhury present at the Benzinga Global Small Cap Conference virtually from December 8-9, 2021. Chowdhury's presentation is scheduled for December 8 at 3:00 PM ET and he will also conduct one-on-one meetings during the event.
The company is commercializing products like sugarBEAT®, a continuous glucose monitor, and proBEAT™, a health tech product aimed at diabetes management. Nemaura is positioned in the growing diabetes market projected to reach $59 billion by 2025.
- None.
- None.
Loughborough, England, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that Chief Executive Officer Faz Chowdhury, Ph.D., will present at the Benzinga Global Small Cap Conference, which is being held virtually from December 8 – December 9, 2021.
Dr. Chowdhury will deliver his corporate presentation on December 8 at 3:00 PM ET.
Dr. Chowdhury will also be available for one-on-one meetings throughout the conference.
Investors can register for the conference here:
https://www.benzinga.com/events/small-cap/december-2021-global/
About Nemaura Medical, Inc.
Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT®diabetes program.
The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly
For more information, please visit www.NemauraMedical.com.
Contact:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com
FAQ
When will Nemaura Medical present at the Benzinga Global Small Cap Conference?
Who will represent Nemaura Medical at the Benzinga conference?
What products is Nemaura Medical commercializing?
What is the projected market size for diabetes management by 2025?
Is sugarBEAT® approved for use?
